Valneva - Pfizer Choose Three-Dose Schedule For Lyme Vaccine Candidate Moving Forward

Valneva SE VALN and Pfizer Inc PFE have reported further Phase 2 data for their Lyme disease vaccine candidate, VLA15. 

  • The Phase 2 trial, VLA15-221, compared the immunogenicity of VLA15 after administration of two or three primary series doses. 
  • In the sub-analysis of adult participants (18-65 years old), VLA15 was immunogenic with both vaccination schedules tested. 
  • These data are consistent with the strong immunogenicity profile observed for this age group in previous Phase 2 studies. 
  • Related: Valneva, Pfizer's Phase 2 Data Suggests Booster Strategy For Lyme Disease Vaccine Candidate.
  • However, the induction of anti-OspA IgG (anti-outer surface protein A immunoglobulin G) antibody titers was higher in participants who received the three-dose primary series compared to the two-dose primary series.
  • Valneva and Pfizer plan to proceed with a three-dose primary series vaccination schedule in a planned Phase 3 trial based on these new results. 
  • The trial will evaluate VLA15 in adults and pediatric subjects five years of age and above and is expected to be initiated in 2022.
  • The VLA15-221 trial is ongoing to assess the safety and immunogenicity of VLA15 in 5-17-year-olds. Initial pediatric data are expected in 1H of 2022.
  • The analysis was also consistent with the acceptable safety and tolerability profile observed in previous studies of VLA15. 
  • No vaccine-related serious adverse events were observed.
  • Price Action: VALN shares closed at $33.56 on Thursday, while PFE stock is down 0.17% at $53.29 during the premarket session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefsPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!